Please login to the form below

Not currently logged in
Email:
Password:

CDK4/6 inhibitor

This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Verzenio scores a win in early-stage breast cancer

Lilly’s Verzenio scores a win in early-stage breast cancer

The two-year distant relapse-free survival rate was 93.6% in the Verzenio arm compared to 90.3% in the control arm. ... The positive results for Verzenio in the early breast cancer setting will be a blow for Pfizer’s rival CDK4/6 inhibitor Ibrance

Latest news

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics